Compare KN & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | VERA |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | KN | VERA |
|---|---|---|
| Price | $23.13 | $48.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $22.33 | ★ $76.60 |
| AVG Volume (30 Days) | 793.8K | ★ 1.3M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $573,500,000.00 | N/A |
| Revenue This Year | $9.26 | N/A |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $54.90 | ★ N/A |
| Revenue Growth | ★ 4.24 | N/A |
| 52 Week Low | $12.19 | $18.53 |
| 52 Week High | $24.54 | $56.05 |
| Indicator | KN | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 56.84 |
| Support Level | $21.90 | $47.28 |
| Resistance Level | $23.60 | $50.79 |
| Average True Range (ATR) | 0.57 | 2.32 |
| MACD | 0.12 | -1.14 |
| Stochastic Oscillator | 73.87 | 28.63 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.